Discovery of Antigen-Mimic sdAb for Vaccine Generation
Creative Biolabs is one of the well-recognized experts who has been long-term devoted to the discovery and application of single domain antibody (sdAb). Based on our extensive experience in developing novel sdAbs, our scientists are pleased to provide the most suitable anti-idiotypic sdAb production service to meet our clients' specific project requirements.
Anti-idiotypic sdAb as Antibody Vaccine or Vaccine Vehicle
Immunotherapy based on the therapeutic antibody is one of the effective treatments; however, it still presents several possible limitations, including the need for repeating injection to achieve a lasting therapeutic effect, the potential drug resistance, and possible toxic effects on some patients. Anti-idiotypic sdAb which mimics epitope of a target protein (especially a toxin) can be used as a substitution for vaccination or as vaccine vehicle. Compared with conventional immunotherapy using therapeutic antibody and nominal antigen vaccine, it is a more attractive and promising approach. With proper design, such antigen-mimic anti-ID sdAb can induce a similar immune response with that triggered from nominal antigens and allows fewer injection doses than using therapeutic antibodies. Furthermore, it offers several main advantages in immunotherapy, including but not limited to:
- Substitution of antigens which are from the non-protein origin, low or no immunogenic, or hard to be obtained
- High specificity and affinity, non-toxicity, non-infectious, fewer side effects
- Establishment of stable and robust humoral and/or cellular immune responses
- Establishment of an immune memory response which persists after the end of treatment and prevents disease recurrence
- Have the potential to act directly on the entire patient population (unrestricted by HLA type) and elicit immunity in the majority of the patients on vaccination
- Overcome the problem of immune tolerance that is associated with most low or no immunogenicity tumor antigens and actively induces a protective response
Fig.1 Antigen mimic sdAb (anti-idiotypic sdAb). (Qiu, et al., 2015)
A vaccine based on anti-idiotypic sdAb is quite a potential immunotherapy tool with excellent specificity, flexibility in design, and without toxicity. It shows extreme refolding capabilities, physical stability, and thermal stability; mimics small molecules and haptens which interact with crevices or cavities at the antibody surfaces in contrast to conventional antibodies. Creative Biolabs now provides one-stop solution for anti-idiotypic sdAb development for the discovery of antigen-mimic vaccines in the field of immunotherapy. The ability of antigen-mimic vaccines to modulate the immune response has shown promising therapeutic effects in different areas such as autoimmune diseases, cancer research, or pathogen infection and the like.
Based on our advanced platforms and professional science teams, Creative Biolabs is always devoted to assisting our customers with the best-fit proposal and the most satisfactory anti-idiotypic sdAb related solutions. If you are interested in our sdAb development services, please feel free to contact us for more details.
Reference
- Qiu, Y.; et al. Deoxynivalenol-mimic nanobody isolated from a naïve phage display nanobody library and its application in immunoassay. Analytica Chimica Acta. 2015, 887: 201-208.
Case Study
We are offering highly customized CRO services to assist your Single Domain Antibody (sdAb) related projects. Please Contact Us for more details.
Applications
